Healing

Ara-290

Peptide · EPO helix B surface peptide · Synthetic

FDA · PHASE 2 TRIALSWADA PROHIBITED

Half-life

~2 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Clinical trial data

Risk

Standard

Overview

Known for

Non-erythropoietic EPO derivative. Activates the innate repair receptor (IRR) without stimulating red blood cell production. Neuroprotective and tissue-protective. Being studied for neuropathic pain and small fiber neuropathy.

Mechanism

Erythropoietin-derived peptide — activates innate repair receptor (IRR) WITHOUT stimulating red blood cell production. Neuroprotective, tissue-protective, anti-inflammatory.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Active
Supply & nature
ExogenousExogenous
FDA category
Phase 2 trials

Evidence & standing

Evidence base
Clinical trial data
Risk level
Standard
Clinical phase
Phase 2
Best studies
6 references
  • Brines et al. (2008) PNAS 105:10925-30 — Non-erythropoietic EPO derivative
  • Brines et al. (2014) Mol Med 20:559-68 — Neuropathic pain pilot
  • Araim Pharmaceuticals development
  • NOT FDA APPROVED
  • Phase 2 data for sarcoidosis and diabetic neuropathy
  • Unique mechanism: innate repair receptor activation without blood cell production

Dosage & protocol

Typical dose
2-4mg
Research range
4–8 µg/kg
Cycle
4 weeks on / 4 weeks off
Onset
10 days first effects
Full effect
42 days
Half-life
~2-3min
~2-3 minutes (IV) | ~10-30 minutes (SubQ)
Protocol

2-4mg SubQ daily or 3x per week. Clinical trials used 2mg IV.

Time to effects

EARLY: 1-2 weeks

FULL: 4-8 weeks

Week 1-2: Neuropathic pain reduction beginning. Tissue-protective effects initiating.

Week 2-4: Significant pain improvement in responsive patients. Nerve function improving.

Week 4-8: Maximum benefit for neuropathic conditions. Small fiber neuropathy improvement measurable.

Most noticeable in patients with neuropathic pain or small fiber neuropathy. Minimum commitment: 4 weeks.

Recommended vial
  • 10mg (only size)

At 2mg/day = 5 days ✓. At 4mg/day = 2.5 days ✓. No shelf life issues.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
WADA status
WADA S2 – Peptide hormones, growth factors
Side effects

Generally well tolerated in trials. Injection site reaction, headache (mild), dizziness. No EPO-like side effects (no polycythaemia/thrombosis).

Interactions

EPO (theoretical interaction at high doses — but Ara-290 doesn't activate classical EPO pathway). Minimal known interactions.

Handle with research caution

No strict contraindications with other peptides on this list.

⚠️ WADA PROHIBITED — S2 category (non-erythropoietic EPO receptor agonists). Do not use in competitive sport.

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
3–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.